June 30

Hertzelia, IL

Receive PMWC updates & offers by email
First:
Last:
Email:

Track 2

"Most Promising Company Award" Competition

Overview

Track 2 offers pre-selected, emerging companies defining the next generation of personalized medicine platforms and technologies the chance to compete for the PMWC 2013 Israel Most Promising Company Award. Companies gain exposure and establish connections with potential clients, partners, investors. The top three companies will be chosen by a panel of VC judges to present in Track 1 (main track) to the judges and the audience, who will then vote on a winner at the end of Day 2, June 30th.

Competition Stages

1Apply

Stage 1: Apply


Company Criteria

Privately-held companies in:


  • Therapeutics
  • Diagnostics
  • Healthtech

 


Apply
2Screening

Stage 2: Screening


Screening Parameters

 

  • Innovation is disruptive to current standard-of-care, both in cost and effectiveness
  • Strength of team and ability to execute
  • Barriers to competition and strength of IP
  • Expected financial returns for investors

 

Companies notified in ~one week

3 Registration

Stage 3: Registration


Registration Benefits

 

  • 10 min presentation
  • 4 min feedback from semi-final judges
  • 2 admissions
  • Exhibition / marketing table
  • Logo on website with link and short description

Approved companies, register here

PMWC 2013 SV FINALS

Know a good company?

NOMINATE

Current Competitors

Ask Medic
Ask Medic

Ask Medic

Ask Medic is a personal health solutions company founded in 2010 to assist healthcare professionals in providing better healthcare, reducing costs and improving customer satisfaction through PHR advanced tools.

BioGenCell
BioGenCell

BioGenCell

BioGenCell's lead product, BGC101, is designed to regenerate blood supply in patients suffering from blood vessel insufficiency and peripheral vascular diseases that cause multiple organ failure. The product, which is based on the patient's own blood, is supplied to the physician in a ready-to-use syringe that is sufficient for a single treatment session with long-lasting therapeutic effects.

Cell Cure Neurosciences
Cell Cure Neurosciences

Cell Cure Neurosciences

Cell Cure Neurosciences is developing a cell therapy product for the treatment of dry age-related macular degeneration, a major disease of aging for which there is no FDA approved treatment.

EarlySense
EarlySense

EarlySense

The EarlySense System is a continuous patient monitoring solution transforming healthcare in hospitals and rehabilitation homes worldwide by monitoring patients’ heart rate, respiratory and movement – without ever touching the patients.

BioCEP
BioCEP

BioCEP

A flow-through, immunomagnetic rare cell isolation platform with improved recovery, purity and viability of target cells that enables the development of novel clinical, therapeutic and diagnostic applications with unmet needs.

BioGaming
BioGaming

BioGaming

BioGaming helps therapists and patients materially improve their physical rehabilitation programs. By using an innovative gamification solution that provides better and quicker rehabilitation results.

ElMindA
ElMindA

ElMindA

ElMindA’s mission is to transform state-of-the-art neuroscience into daily clinical practice for every neurology and psychiatry clinic with objective measurement and augmentation of brain function, dysfunction, disease progression and recovery.

Enlivex Therapeutics Ltd
Enlivex Therapeutics Ltd

Enlivex Therapeutics Ltd

Owned by Hadassah Medical Center, Enlivex is developing a patient-specific (HLA matched) cell therapy drug product (ApoCell) comprised of early, stable apoptotic cells for GVHD and other autoimmune and inflammatory conditions. ApoCell uses a physiological mechanism to induce tolerance while avoiding harmful immune suppression means.

Genefron Ltd.
Genefron Ltd.

Genefron Ltd.

Genefron Ltd. is an Israeli company specializing in analyzing genomic data using bioinformatics novel developments allowing personal based genomic diagnostics and treatment.

Improdia
Improdia

Improdia

IMPRODIA designs prognostic/diagnostic kits using biomarkers for detecting the immune status of a large group of diseases characterized by chronic inflammation and ensuing immunosuppression.

Innovo Mimetics
Innovo Mimetics

Innovo Mimetics

Innovo Mimetics' technology lets doctors and researchers test cancer drugs on patients' actual tumor cells before commencing treatment.

Kyma Medical Technologies
Kyma Medical Technologies

Kyma Medical Technologies

Kyma Medical Technologies has developed an innovative approach for remote monitoring of heart failure (CHF) patients. The leading cause of re-hospitalizations for CHF patients is fluid build-up in the lungs (pulmonary congestion), a possibly fatal condition. Hospitalizations inflict a substantial cost burden on the healthcare system. Kyma is about to change the way monitoring is done for the benefit of the patients and the health system.

Marx Biotechnology
Marx Biotechnology

Marx Biotechnology

Marx Biotechnology, which is presently focused on developing a diagnostic kit for the early detection of Graft-versus-Host-Disease (GVHD), is dedicated to providing novel diagnostic and therapeutic solutions.

MediSafe
MediSafe

MediSafe

MediSafe Project is a cloud-based Medication Relations Management system, focused on solving non adherence for pharma companies – raising adherence from 50% to 80% reported adherence, with over 2,000,000 doses.

MedPal Health Solutions
MedPal Health Solutions

MedPal Health Solutions

MedPal aims to enhance patients’ quality of life, reduce healthcare costs, and increase medication sales with comprehensive medication compliance solutions.

Nucleix
Nucleix

Nucleix

Nucleix is a biotechnology company focused on the development and commercialization of non-invasive, molecular diagnostic tests utilizing our revolutionary MethyMatics™ and MethylPrecise™ technologies. Our first product, Bladder EpiCheck™ is a urine test based on identification of multiple methylated cancer DNA biomarkers for diagnosis and surveillance of bladder cancer.

Oxitone Medical
Oxitone Medical

Oxitone Medical

10 million people die yearly from sudden cardiac/pulmonary dysfunction. 100 million at the significant risk of death. 40% of attacks happen unwitnessed. Oxitone’s mission is to dramatically improve patient safety.

SenseWiser
SenseWiser

SenseWiser

Sensewiser is developing novel solutions for non-intrusive health monitors to be used in Telehealth and Mobile health applications.

Partial List of Past VCs and Financial participants

 

7Health Ventures
Aberdare Ventures
AccelusHealth Partners
Advanced Technology Ventures
Anthem Venture Partners
Burril & Company
Caldwell Partners Intl.
Charter Life Sciences
Claremont Creek Ventures
CMEA
Cowper Street Angels
Crosslink Capital
DFJ Tamir Fishman Ventures
Draper Fisher Jurvetson
Edgewood Venture Partners
EDventure Holdings
Enterprise Partners Venture Capital
Evolvence India Life Science Fund
Geisinger Ventures
Giza Venture Capital
Goldman Sachs
Halo Fund III
HealthTech Capital
Horizon Ventures
IBM Venture Capital Group
Interwest Partners
KPCB
Lazard
Life Tech Capital
Lighthouse Capital Partners
Longitude Capital
MDV
Medica Venture Partners
MedStars
Merck & Co.
Miramar Venture Partners
Morgan Stanley
Morgenthaler Ventures
Muir Partners
New Biology Ventures, LLC Oppenheimer & Co.
Orbimed
Physic Ventures
Pitango
Prospect Venture Partners
RBC Capital Markets
SDL Ventures
Sequoia Capital
Silicon Valley Bank
Skyline Ventures
Sutter Hill Ventures
SVB Accelerator
Telegraph Hill Partners
The Angels' Forum
TPG Biotech
Third Rock Ventures
USVP
Uzia Initiatives & Management
Vivo Ventures

 

    This entire site is licensed under Creative Commons Attribution-NoDerivs.   |   © Copyright PMWC International